All In Biotech

NDA 216203 · Lexicon Pharms INC

Inpefa

Sotagliflozin · Oral · Sodium-Glucose Cotransporter 2 Inhibitor

Novel

CDER novel approval, May 26, 2023: To treat heart failure

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 26, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

54

22 Phase 3, 4 recruiting

FAERS reports

557

202 serious, 50 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 12, 2026.

INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors INPEFA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure ( 1 ) or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors ( 1 )

Mechanism: Sotagliflozin is an inhibitor of SGLT2 and SGLT1. Inhibiting SGLT2 reduces renal reabsorption of glucose and sodium which may influence several physiological functions such as lowering both pre-and afterload of the heart and downregulating sympathetic activity. Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium which likely contributes to diarrhea. The mechanism for sotagliflozin's cardiovascular benefits has not been established.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • INPEFA · SOTAGLIFLOZIN 400MG · TABLET, ORAL · Prescription
  • INPEFA · SOTAGLIFLOZIN 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sotagliflozin" as an intervention, any sponsor and status, largest first.

All 54 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness54
  • diarrhoea50
  • death47
  • therapy interrupted37
  • dyspnoea28
  • off label use27
  • product use issue27
  • urinary tract infection25
  • headache23
  • nausea19
  • fungal infection17
  • drug ineffective15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20186
20193
20203
20212
20221
202345
2024296
2025146
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inpefa (Sotagliflozin)

2024 spending

$5.9M

Beneficiaries

2,006

7,368 claims

Per beneficiary

$2,922

$19.33 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$659,182
2024$5,862,205

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 96 on PubMed

Sponsor: Lexicon Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.